Ladenburg upgraded NextCure (NXTC) to Buy from Neutral with an $18 price target The firm says SIM0505 has a “clear roadmap” to become a “best-in-class” antibody drug conjugate that targets CDH6 for the treatment of advanced solid tumors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXTC:
- NextCure Advances Cancer Therapies Amid Financial Adjustments
- NextCure reports Q3 EPS ($3.22), consensus ($3.98)
- NextCure’s Phase I Study of SIM0505: A Potential Breakthrough in Cancer Treatment
- NextCure’s Promising Phase 1 Study on LNCB74: A Potential Game-Changer in Cancer Treatment
- NextCure, Simcere Zaiming announce expansion of Phase 1 trial of SIM0505